Role of artificial intelligence in imaging and endoscopy for the diagnosis, monitoring and prognostication of inflammatory bowel disease: a scoping review protocol.

Inflammatory bowel diseases (IBD) are immune-mediated conditions that are increasing in incidence and prevalence worldwide. Their assessment and monitoring are becoming increasingly important, though complex. The best disease control is achieved through tight monitoring of objective inflammatory parameters (such as serum and stool inflammatory markers), cross-sectional imaging and endoscopic assessment. Considering the complexity of the information obtained throughout a patient's journey, artificial intelligence (AI) provides an ideal adjunct to existing tools to help diagnose, monitor and predict the course of disease of patients with IBD. Therefore, we propose a scoping review assessing AI's role in diagnosis, monitoring and prognostication tools in patients with IBD. We aim to detect gaps in the literature and address them in future research endeavours. We will search electronic databases, including Medline, Embase, Cochrane CENTRAL, CINAHL Complete, Web of Science and IEEE Xplore. Two reviewers will independently screen the abstracts and titles first and then perform the full-text review. A third reviewer will resolve any conflict. We will include both observational studies and clinical trials. Study characteristics will be extracted using a data extraction form. The extracted data will be summarised in a tabular format, following the imaging modality theme and the study outcome assessed. The results will have an accompanying narrative review. Considering the nature of the project, ethical review by an institutional review board is not required. The data will be presented at academic conferences, and the final product will be published in a peer-reviewed journal.

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: Dr MC reports consulting fees from Prometheus Laboratories. LK reports no competing interests at this time. Dr MA reports consulting fees from Nikkiso Europe, Mundipharma, Janssen, Abbvie, Ferring, and Pfizer. Dr NKC is a consultant for NeuroLogica, a subsidiary of Samsung Electronics, a consultant to Takeda, and a speaker for Bristol Myers Squibb. Dr MD is a consultant for Neurologica corp., a subsidiary of Samsung electronics co., ltd. Dr TSR is employed by Motilent Ltd. and majority shareholder of Pinfold Technologies. Dr DTR has received grant support from Takeda; and has served as a consultant for Abbvie, Abgenomics, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corp, Syneos, Dizal Pharmaceuticals, Genentech/Roche, Gilead Sciences, Ichnos Sciences SA, InDex Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Pfizer, Prometheus Laboratories, Prometheus Biosciences, Reistone, Takeda, and Techlab. Dr SS reports lecture fees from AbbVie, Takeda Pharmaceutical, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, Canon, and Zeria Pharmaceutical and as an endowed chair for AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical and EA Pharma and served as an advisory board member for Janssen Pharmaceutical. Dr BV reports the following conflicts (all outside of the submitted work): Research support from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares, and Takeda. Speaker’s fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris. Consultancy fees from Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma, and Viatris. Dr KLN reports relationships with AbbVie, Janssen, Takeda, Pfizer, Amgen, Bristol-Myers Squibb, Celltrion, Pendopharm, Fresnius Kabi, Samsung, Philips.